FIGURE 2.

(A) Tissue biodistribution of ¹¹¹In-DOTA-5D3 in male NOD-SCID mice bearing PSMA(+) PC3 PIP and PSMA(−) PC3 flu tumors on either flank (n = 4). (B) Selected PSMA(+) PC3 PIP tumor-to-normal organ ratios. (C) Binding specificity assessed by blockade with coinjection of either 10- or 50-fold excess of nonradiolabeled 5D3. (D) Immunohistochemistry of PSMA expression and negative control (no PSMA staining) of frozen tissue sections of PSMA(+) PC3 PIP tumor and PSMA(−)PC3 flu tumor at ×10 magnification obtained from biodistribution experiment at 24 h after injection of ¹¹¹In-DOTA-5D3 and from blocking experiment at 24 h using 50-fold excess of 5D3.